242 related articles for article (PubMed ID: 24119483)
1. Impact of emerging hepatitis C virus treatments on future needs for liver transplantation in France: a modelling approach.
Deuffic-Burban S; Mathurin P; Rosa I; Bouvier AM; Cannesson A; Mourad A; Canva V; Louvet A; Deltenre P; Boleslawski E; Truant S; Pruvot FR; Dharancy S
Dig Liver Dis; 2014 Feb; 46(2):157-63. PubMed ID: 24119483
[TBL] [Abstract][Full Text] [Related]
2. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
[TBL] [Abstract][Full Text] [Related]
3. Evidence of Spontaneous Post-transplant HCV Eradication in Two Failed DAA Treatments Awaiting Liver Transplantation.
Lenci I; Bosa A; Milana M; Baiocchi L; Antonucci FP; Aragri M; Ceccherini-Silberstein F; Perno CF; Tisone G; Angelico M
Dig Dis Sci; 2017 Aug; 62(8):2193-2195. PubMed ID: 28500586
[No Abstract] [Full Text] [Related]
4. Predicted effects of treatment for HCV infection vary among European countries.
Deuffic-Burban S; Deltenre P; Buti M; Stroffolini T; Parkes J; Mühlberger N; Siebert U; Moreno C; Hatzakis A; Rosenberg W; Zeuzem S; Mathurin P
Gastroenterology; 2012 Oct; 143(4):974-85.e14. PubMed ID: 22863764
[TBL] [Abstract][Full Text] [Related]
5. Antiviral treatment for cirrhosis due to hepatitis C: a review.
Somasundaram A; Venkataraman J
Singapore Med J; 2012 Apr; 53(4):231-5. PubMed ID: 22511042
[TBL] [Abstract][Full Text] [Related]
6. [Hepatitis C and liver transplantation].
Durand F
Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B82-90. PubMed ID: 12180312
[No Abstract] [Full Text] [Related]
7. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
[TBL] [Abstract][Full Text] [Related]
8. Infections and organ transplantation: new challenges for prevention and treatment of hepatitis C virus.
Burra P; De Martin E
Transplant Proc; 2011; 43(6):2455-6. PubMed ID: 21839292
[TBL] [Abstract][Full Text] [Related]
9. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
[TBL] [Abstract][Full Text] [Related]
10. The future of liver transplantation for viral hepatitis.
Durand F; Francoz C
Liver Int; 2017 Jan; 37 Suppl 1():130-135. PubMed ID: 28052618
[TBL] [Abstract][Full Text] [Related]
11. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
Shindo M; Ken A; Okuno T
Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
[TBL] [Abstract][Full Text] [Related]
12. [Cirrhosis due to hepatitis C virus].
Trinchet JC
Rev Prat; 2000 May; 50(10):1094-9. PubMed ID: 10905095
[TBL] [Abstract][Full Text] [Related]
13. Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma.
Leone N; Rizzetto M
Minerva Gastroenterol Dietol; 2005 Mar; 51(1):31-46. PubMed ID: 15756144
[TBL] [Abstract][Full Text] [Related]
14. A patient with hepatitis C-related cirrhosis and hepatocellular carcinoma who was cured with an orthotopic liver transplantation and interferon therapy.
Shibata M; Yanaga K; Morizane T; Yanagawa T; Hirakawa M; Ueno Y; Esquivel CO; Mitamura K
J Gastroenterol; 2003; 38(6):598-602. PubMed ID: 12858850
[TBL] [Abstract][Full Text] [Related]
15. Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation.
de Arias AE; Haworth SE; Belli LS; Burra P; Pinzello G; Vangeli M; Minola E; Guido M; Boccagni P; De Feo TM; Torelli R; Cardillo M; Scalamogna M; Poli F
Liver Transpl; 2009 Apr; 15(4):390-9. PubMed ID: 19326408
[TBL] [Abstract][Full Text] [Related]
16. Projecting future complications of chronic hepatitis C in the United States.
Davis GL; Albright JE; Cook SF; Rosenberg DM
Liver Transpl; 2003 Apr; 9(4):331-8. PubMed ID: 12682882
[TBL] [Abstract][Full Text] [Related]
17. Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality.
Cramp ME; Rosenberg WM; Ryder SD; Blach S; Parkes J
BMC Gastroenterol; 2014 Aug; 14():137. PubMed ID: 25100159
[TBL] [Abstract][Full Text] [Related]
18. Viral hepatitis in solid organ transplantation other than liver.
Vallet-Pichard A; Fontaine H; Mallet V; Pol S
J Hepatol; 2011 Aug; 55(2):474-82. PubMed ID: 21241754
[TBL] [Abstract][Full Text] [Related]
19. Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting.
Perricone G; Duvoux C; Berenguer M; Cortesi PA; Vinaixa C; Facchetti R; Mazzarelli C; Rockenschaub SR; Martini S; Morelli C; Monico S; Volpes R; Pageaux GP; Fagiuoli S; Belli LS;
Liver Int; 2018 Dec; 38(12):2170-2177. PubMed ID: 29750389
[TBL] [Abstract][Full Text] [Related]
20. Natural histories of hepatitis C virus infection in men and women simulated by the Markov model.
Tanaka J; Kumada H; Ikeda K; Chayama K; Mizui M; Hino K; Katayama K; Kumagai J; Komiya Y; Miyakawa Y; Yoshizawa H
J Med Virol; 2003 Jul; 70(3):378-86. PubMed ID: 12767000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
